Abigail Lewis

The therapy is intended to restore hearing and support early speech development in children with OTOF-related congenital deafness.

The vice president of neuroscience at Voyager Therapeutics shared preclinical data on the company’s AAV-delivered RNA interference therapy, VY-1706.

The senior director at Regeneron discussed the company’s receptor-driven approach to AAV targeting, leveraging antibody engineering to enhance tissue specificity and reduce off-target effects.

Ocugen initiates pivotal confirmatory trial for OCU410ST, its second modifier gene therapy candidate, in patients with Stargardt disease.

Atsena Therapeutics will advance ATSN-201 into a pivotal phase 1/2/3 trial following FDA agreement on study design and endpoints.